Literature DB >> 14575419

Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.

Magdalena Jakubiak-Wielganowicz1, Robert Kubiak, Jacek Sygut, Lech Pomorski, Radzisław Kordek.   

Abstract

Galectin-3 was primarily reported to be a marker distinguishing thyroid adenomas and carcinomas. To check the usefulness of anti-galectin-3 immunohistochemistry, we studied its expression in 42 follicular adenomas and 42 follicular carcinomas. Eight cases out of 42 follicular adenomas (19%) presented focal or diffuse galectin-3 immunoexpression. From 42 cases of follicular carcinomas, six cases did not present galectin-3 immunopositivity at all. Three of these cases were widely invasive (one with focal anaplastic feature and one oxyphilic), and three other ones were minimally invasive. Two other carcinoma cases had only small foci positive with galectin-3 antibody, thirteen cases presented positivity mostly restricted to peripheral part of the tumor and 21 cases possessed diffuse, strong reaction. Two adenomas presented galectin-3 positive foci, and these cells had light nuclear changes superficially suggesting follicular variant of papillary carcinoma, mostly because of nuclear clearing. In these tumors, adenoma diagnosis was supported by experts, but we can not exclude that they represent early phase of malignisation, although such theory needs to be prooved. Our study does not allow to use galectin-3 as a highly specific marker, differentiating between follicular benign and malignant tumor, although it may be used as an additive tool.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575419

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  7 in total

1.  ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

2.  Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.

Authors:  Bogdan Galusca; Jean Marc Dumollard; Sandrine Lassandre; Alain Niveleau; Jean Michel Prades; Bruno Estour; Michel Peoc'h
Journal:  Virchows Arch       Date:  2005-05-13       Impact factor: 4.064

3.  Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.

Authors:  A Carpi; A G Naccarato; G Iervasi; A Nicolini; G Bevilacqua; P Viacava; P Collecchi; L Lavra; C Marchetti; S Sciacchitano; A Bartolazzi
Journal:  Br J Cancer       Date:  2006-06-27       Impact factor: 7.640

Review 4.  Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Camilla Virili; Francesco Romanelli; Anna Crescenzi; Luca Giovanella
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

5.  Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.

Authors:  Dalia A Elsers; Mahmoud R A Hussein; Mohammed Hassan Osman; Ghada A Mohamed; Ghada Hosny
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

Review 6.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

7.  Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.

Authors:  Duško Dunđerović; Jasmina Marković Lipkovski; Ivan Boričic; Ivan Soldatović; Vesna Božic; Dubravka Cvejić; Svetislav Tatić
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.